Edition:
United Kingdom

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

47.18CHF
3:24pm BST
Change (% chg)

CHF-0.62 (-1.30%)
Prev Close
CHF47.80
Open
CHF48.18
Day's High
CHF48.54
Day's Low
CHF47.10
Volume
19,608
Avg. Vol
65,737
52-wk High
CHF84.10
52-wk Low
CHF47.10

Select another date:

Tue, Aug 14 2018

BRIEF-Basilea Pharmaceutica Sees 2018 Oper Loss At CHF 25-35 Mln

* H1 OPERATING LOSS OF CHF 20.4 MILLION COMPARED TO CHF 19.1 MILLION IN H1 2017

BRIEF-Basilea Pharmaceutica: Approval For Antifungal Cresemba (Isavuconazole) In Jordan

* HIKMA PHARMACEUTICALS LLC, GAINED REGULATORY APPROVAL FOR ANTIFUNGAL CRESEMBA (ISAVUCONAZOLE) IN JORDAN Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Starts Clinical Phase 3 Study With Antibiotic Ceftobiprole In Staphylococcus Aureus Bacteremia

* BASILEA STARTS CLINICAL PHASE 3 STUDY WITH ANTIBIOTIC CEFTOBIPROLE IN STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Pharmaceutica Reports Receipt Of Payment Based On First Cresemba Approval In Latin America

* REPORTS RECEIPT OF MILESTONE PAYMENT BASED ON FIRST CRESEMBA® APPROVAL IN LATIN AMERICA

BRIEF-Basilea Pharmaceutica Starts Clinical Phase 2A Expansion With Bal101553 In Ovarian Cancer And Glioblastoma

* STARTS CLINICAL PHASE 2A EXPANSION WITH BAL101553 IN OVARIAN CANCER AND GLIOBLASTOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Pharmaceutica Appoints Gerrit Hauck As CTO

* GERRIT HAUCK APPOINTED AS CHIEF TECHNOLOGY OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea: Start Of Clinical Phase 3 Study In Japan

* BASILEA REPORTS START OF CLINICAL PHASE 3 STUDY IN JAPAN BY ASAHI KASEI PHARMA WITH ANTIFUNGAL ISAVUCONAZOLE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib

* ARQULE AND BASILEA ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DERAZANTINIB IN THE US, EU, JAPAN AND REST OF WORLD EXCLUDING GREATER CHINA

BRIEF-Basilea Pharmaceutica Licenses Late-Stage Oncology Drug Candidate Derazantinib

* LICENSES LATE-STAGE ONCOLOGY DRUG CANDIDATE DERAZANTINIB FROM ARQULE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: